Daniel Dupret
Präsident bei AzurRx BioPharma SAS
Aktive Positionen von Daniel Dupret
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
AzurRx BioPharma SAS
 AzurRx BioPharma SAS Miscellaneous Commercial ServicesCommercial Services Part of First Wave Biopharma, Inc., AzurRx BioPharma SAS is a French company that provides bioscience and biotechnology research and development services. The company is based in Langlade, France. AzurRx BioPharma was acquired by First Wave Biopharma, Inc. from Protea Biosciences Group, Inc. on June 13, 2014 for $2.20 million. | Präsident | 01.10.2008 | - |
Karriereverlauf von Daniel Dupret
Ehemalige bekannte Positionen von Daniel Dupret
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ENTERO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2014 | 01.07.2019 |
Protéus SA
 Protéus SA BiotechnologyHealth Technology Protéus SA discovers, engineers, and manufactures proteins for industrial applications. It operates as a biotechnology company that focuses on the discovery, engineering and manufacturing of proteins of industrial interest, and on the development of protein-based bioprocesses. The company was founded on August 11, 1998 and is headquartered in Paris, France. | Vorstandsvorsitzender | 01.01.1998 | 01.01.2007 |
| Gründer | 01.01.1998 | 01.01.2007 | |
| Präsident | 01.01.1998 | 01.01.2007 | |
| University of Nimes | Präsident | 01.01.2003 | 01.01.2007 |
Appligene Oncor SA
 Appligene Oncor SA Pharmaceuticals: OtherHealth Technology Part of Valiant Co., Ltd., Appligene Oncor SA is a French company that specializes in medicinal chemicals and botanical products. The company is based in Illkirch Graffenstaden, France. The company was founded by Daniel Dupret. Appligene Oncor was acquired by Quantum Biotechnologies, Inc. on February 17, 1999 for $1.24 million. | Vorstandsvorsitzender | 01.01.1985 | 01.01.1998 |
| Gründer | 01.01.1985 | 01.01.1998 | |
| Präsident | 01.01.1985 | 01.01.1998 |
Ausbildung von Daniel Dupret
| Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
| University of Strasbourg | Doctorate Degree |
Statistik
International
| Frankreich | 7 |
| Vereinigte Staaten | 2 |
Operativ
| President | 4 |
| Chief Executive Officer | 2 |
| Founder | 2 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENTERO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
AzurRx BioPharma SAS
AzurRx BioPharma SAS Miscellaneous Commercial ServicesCommercial Services Part of First Wave Biopharma, Inc., AzurRx BioPharma SAS is a French company that provides bioscience and biotechnology research and development services. The company is based in Langlade, France. AzurRx BioPharma was acquired by First Wave Biopharma, Inc. from Protea Biosciences Group, Inc. on June 13, 2014 for $2.20 million. | Commercial Services |
Protéus SA
Protéus SA BiotechnologyHealth Technology Protéus SA discovers, engineers, and manufactures proteins for industrial applications. It operates as a biotechnology company that focuses on the discovery, engineering and manufacturing of proteins of industrial interest, and on the development of protein-based bioprocesses. The company was founded on August 11, 1998 and is headquartered in Paris, France. | Health Technology |
Appligene Oncor SA
Appligene Oncor SA Pharmaceuticals: OtherHealth Technology Part of Valiant Co., Ltd., Appligene Oncor SA is a French company that specializes in medicinal chemicals and botanical products. The company is based in Illkirch Graffenstaden, France. The company was founded by Daniel Dupret. Appligene Oncor was acquired by Quantum Biotechnologies, Inc. on February 17, 1999 for $1.24 million. | Health Technology |
| University of Nimes |
- Börse
- Insiders
- Daniel Dupret
- Erfahrung
